TREM2 Agonist Therapies for Alzheimer's Disease

TREM2 Agonist Therapies for Alzheimer's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonist Therapies for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Risk Increase</td>
</tr>
<tr>
<td class="label">R47H</td>
<td>~3-4x</td>
</tr>
<tr>
<td class="label">R62H</td>
<td>~2x</td>
</tr>
<tr>
<td class="label">H157Y</td>
<td>~3x</td>
</tr>
<tr>
<td class="label">T96K</td>
<td>~2x</td>
</tr>
<tr>
<td class="label">Y38C</td>
<td>~5x</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">LAKE</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">INVOKE-2 extension</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Expected Change</td>
</tr>
<tr>
<td class="label">sTREM2</td>
<td>Increase</td>
</tr>
<tr>
<td class="label">[NfL](/proteins/nfl-protein)</td>
<td>Decrease</td>
</tr>
<tr>
<td class="label">p-[tau](/proteins/tau)</td>
<td>Decrease</td>
</tr>
<tr>
<td class="label">[Aβ42](/proteins/amyloid-beta)</td>
<td>Increase (in CSF)</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Lecanemab</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Donanemab</td>
<td

TREM2 Agonist Therapies for Alzheimer's Disease

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">TREM2 Agonist Therapies for Alzheimer's Disease</th>
</tr>
<tr>
<td class="label">Variant</td>
<td>Risk Increase</td>
</tr>
<tr>
<td class="label">R47H</td>
<td>~3-4x</td>
</tr>
<tr>
<td class="label">R62H</td>
<td>~2x</td>
</tr>
<tr>
<td class="label">H157Y</td>
<td>~3x</td>
</tr>
<tr>
<td class="label">T96K</td>
<td>~2x</td>
</tr>
<tr>
<td class="label">Y38C</td>
<td>~5x</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">INVOKE-2</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">LAKE</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">INVOKE-2 extension</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Expected Change</td>
</tr>
<tr>
<td class="label">sTREM2</td>
<td>Increase</td>
</tr>
<tr>
<td class="label">[NfL](/proteins/nfl-protein)</td>
<td>Decrease</td>
</tr>
<tr>
<td class="label">p-[tau](/proteins/tau)</td>
<td>Decrease</td>
</tr>
<tr>
<td class="label">[Aβ42](/proteins/amyloid-beta)</td>
<td>Increase (in CSF)</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Lecanemab</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Donanemab</td>
<td>Enhanced plaque clearance</td>
</tr>
<tr>
<td class="label">TREM2 agonist + Aducanumab</td>
<td>Microglial activation</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company</td>
</tr>
<tr>
<td class="label">AT877</td>
<td>Astria</td>
</tr>
</table>

Trem2 Agonist Therapies For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

[TREM2](/proteins/trem2-protein) is a receptor expressed primarily on [microglia](/cell-types/microglia-neuroinflammation) in the brain that plays a critical role in the brain's immune response to amyloid pathology. TREM2 variants, particularly the R47H variant, significantly increase Alzheimer's disease risk by impairing microglial function. TREM2 agonist therapies aim to enhance microglial clearance of amyloid plaques and reduce neuroinflammation[@wang2015]. [@guerreiro2013]

The TREM2 gene encodes a transmembrane receptor that is highly expressed on microglia in the brain. Loss-of-function variants in TREM2 increase the risk of developing Alzheimer's disease by approximately 3-4 fold, highlighting the critical role of microglial function in disease pathogenesis[@guerreiro2013]. [@kerenshaul2017]

Mechanism of Action

TREM2 Signaling Pathway

TREM2 is a cell surface receptor that triggers intracellular signaling through the adaptor protein DAP12 (TYROBP): [@song2017]

Aβ or lipid ligands → TREM2 activation → DAP12 ITAM phosphorylation
→ SYK activation → PI3K/Akt, MAPK pathways → Functional outcomes:
├── Enhanced phagocytosis of Aβ
├── Reduced inflammatory cytokine production
├── Improved microglial metabolic fitness
└── Promotion of disease-associated microglia (DAM)

Disease-Associated Microglia (DAM)

TREM2 activation promotes the transition from homeostatic microglia to disease-associated microglia (DAM), which are more effective at clearing amyloid plaques and protecting [neurons](/entities/neurons)[@kerenshaul2017]. The DAM program involves: [@schlepckow2020]

• Phase 1 DAM: Triggered by TREM2 activation, leads to phagocytic microglia
• Phase 2 DAM: Further activation with IFN-γ signaling, highly protective

Lipid Ligand Recognition

TREM2 recognizes lipid moieties on modified proteins and apolipoproteins. Key ligands include: [@cai2024]

• [Apolipoprotein E](/proteins/apoe) (apoE) lipidation state
• HDL-like particles
• Amyloid-associated lipids
• Phosphatidylserine exposure on apoptotic cells

Genetic Evidence

TREM2 Variants and Alzheimer's Risk

The R47H variant is particularly notable as it specifically impairs the ability of TREM2 to bind to amyloid-associated lipids while partially retaining responsiveness to other ligands[@song2017].

Clinical Development

AL002 (Alector/AbbVie)

AL002 is a monoclonal antibody designed to activate TREM2:

Mechanism: AL002 binds to the extracellular domain of TREM2, promoting receptor clustering and downstream signaling in the absence of endogenous ligands.

AL003 (Alector)

AL003 takes a different approach, potentially enhancing TREM2 signaling through a different epitope and Fc-mediated effects.

NI-220 (Novo Nordisk)

A TREM2-targeting antibody in early development, representing Novo Nordisk's entry into the Alzheimer's therapeutic space.

Biomarker Correlates

CSF Biomarker Changes Expected with TREM2 Agonism

Challenges and Considerations

Potential Risks

Patient Selection

• TREM2 variant carriers may respond differently
• Early AD patients ( MCI due to AD, mild AD dementia)
• Amyloid-positive by PET or CSF biomarkers

See Also

• [TREM2 Gene](/proteins/trem2)
• [Microglia in Alzheimer's](/entities/microglia)
• [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
• [Disease-Associated Microglia](/cell-types/disease-associated-microglia)

Background

The study of Trem2 Agonist Therapies For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Combination Therapy Potential

TREM2 Agonists + Anti-Amyloid Antibodies

The combination approach addresses both:

Future Directions

Competitive Landscape

Market Potential

• Large unmet need in Alzheimer's disease
• First disease-modifying approach targeting microglia
• Potential for combination therapy market

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Prefrontal sensory gating circuit restoration via PV interneuron enhancement](/hypothesis/h-62f9fc90) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: PVALB
• [Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2
• [GFAP-Positive Reactive Astrocyte Subtype Delineation](/hypothesis/h-seaad-56fa6428) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: GFAP
• [Excitatory Neuron Vulnerability via SLC17A7 Downregulation](/hypothesis/h-seaad-7f15df4c) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: SLC17A7

• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-01-gap-001) &#x1f504;
• [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) &#x1f504;
• [TREM2 agonism vs antagonism in DAM microglia](/analysis/SDA-2026-04-02-gap-001) &#x1f504;
• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;